GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Swedish Orphan Biovitrum AB (publ) SOBI.ST · SEK

Health Care · Nasdaq Stockholm · 🇸🇪 Sweden

Compare

496.60

-0.32%

Close of 9 Nov 2026, in SEK

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in SEK, from our data supplier.

FY2025

Revenue

SEK 28.24bn

FY2016FY2025

Net income

SEK 478.0m

FY2016FY2025

Free cash flow

SEK 8.52bn

FY2016FY2025

Shareholders' equity

SEK 37.72bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueSEK 28.24bnSEK 26.03bnSEK 22.12bnSEK 18.79bnSEK 15.53bnSEK 15.26bnSEK 14.25bnSEK 9.14bnSEK 6.51bnSEK 5.20bn
Research and developmentSEK 3.25bnSEK 3.54bnSEK 2.80bnSEK 2.35bnSEK 1.99bnSEK 1.59bnSEK 1.50bnSEK 1.09bnSEK 907.7mSEK 777.6m
Operating incomeSEK 8.05bnSEK 5.63bnSEK 4.07bnSEK 3.81bnSEK 3.73bnSEK 4.82bnSEK 4.53bnSEK 3.12bnSEK 1.60bnSEK 1.13bn
Net incomeSEK 478.0mSEK 3.88bnSEK 2.41bnSEK 2.64bnSEK 2.68bnSEK 3.25bnSEK 3.30bnSEK 2.42bnSEK 1.15bnSEK 809.1m
Diluted earnings per share1.3711.197.038.439.0111.0011.238.974.273.01

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsSEK 67.43bnSEK 75.44bnSEK 74.03bnSEK 52.50bnSEK 48.66bnSEK 48.28bnSEK 45.66bnSEK 17.18bnSEK 10.90bnSEK 9.97bn
Cash and short-term investmentsSEK 1.04bnSEK 1.14bnSEK 904.0mSEK 1.36bnSEK 1.04bnSEK 404.0mSEK 737.0mSEK 3.00bnSEK 1.48bnSEK 785.8m
Total liabilitiesSEK 29.71bnSEK 35.15bnSEK 40.16bnSEK 25.97bnSEK 25.46bnSEK 28.08bnSEK 28.73bnSEK 8.14bnSEK 4.20bnSEK 4.62bn
DebtSEK 11.49bnSEK 16.73bnSEK 20.48bnSEK 9.10bnSEK 10.91bnSEK 14.57bnSEK 16.56bnSEK 3.0mSEK 5.0mSEK 504.0m
Shareholders' equitySEK 37.72bnSEK 40.29bnSEK 33.87bnSEK 26.52bnSEK 23.20bnSEK 20.21bnSEK 16.93bnSEK 9.04bnSEK 6.70bnSEK 5.35bn
Shares outstanding349m347m343m313m297m295m294m270m269m269m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsSEK 8.56bnSEK 7.39bnSEK 4.47bnSEK 4.58bnSEK 5.47bnSEK 5.21bnSEK 3.63bnSEK 2.09bnSEK 1.33bnSEK 342.9m
Capital spending−SEK 40.0m−SEK 3.00bn−SEK 4.94bn−SEK 1.48bn−SEK 370.0m−SEK 3.85bn−SEK 9.75bn−SEK 577.9m−SEK 139.4m−SEK 164.5m
Free cash flowSEK 8.52bnSEK 4.38bn−SEK 473.0mSEK 3.10bnSEK 5.10bnSEK 1.36bn−SEK 6.11bnSEK 1.51bnSEK 1.19bnSEK 178.4m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueSEK 7.84bnSEK 7.18bnSEK 7.82bnSEK 7.78bnSEK 6.17bnSEK 6.46bnSEK 7.44bnSEK 6.89bn
Operating incomeSEK 2.07bnSEK 1.87bnSEK 2.85bnSEK 2.83bnSEK 1.23bnSEK 1.36bnSEK 1.66bnSEK 2.04bn
Net incomeSEK 1.10bnSEK 1.32bnSEK 1.86bn−SEK 2.90bnSEK 636.0mSEK 875.0mSEK 1.40bnSEK 1.46bn
Diluted earnings per share3.133.775.34-8.301.822.514.034.22
Cash from operationsSEK 1.91bnSEK 1.13bnSEK 2.98bnSEK 1.84bnSEK 1.45bnSEK 2.29bnSEK 1.80bnSEK 1.20bn
Capital spending−SEK 340.0m−SEK 254.0m−SEK 5.0m−SEK 8.0m−SEK 421.0m−SEK 11.0m−SEK 61.0m−SEK 2.18bn
Free cash flowSEK 1.57bnSEK 872.0mSEK 2.98bnSEK 1.83bnSEK 1.03bnSEK 2.28bnSEK 1.74bn−SEK 978.0m
Total assetsSEK 82.89bnSEK 81.26bnSEK 67.43bnSEK 66.96bnSEK 68.75bnSEK 70.12bnSEK 75.44bnSEK 72.19bn
Cash and short-term investmentsSEK 1.08bnSEK 940.0mSEK 1.04bnSEK 1.04bnSEK 1.06bnSEK 997.0mSEK 1.14bnSEK 594.0m
DebtSEK 17.34bnSEK 18.80bnSEK 11.49bnSEK 13.59bnSEK 12.81bnSEK 14.02bnSEK 16.73bnSEK 17.61bn
Shareholders' equitySEK 42.26bnSEK 40.38bnSEK 37.72bnSEK 35.98bnSEK 39.06bnSEK 39.03bnSEK 40.29bnSEK 37.09bn

Financial ratios

Data as of 7 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Operating margin28.5%21.6%18.4%20.3%24.0%31.6%
Net margin1.7%14.9%10.9%14.0%17.3%21.3%
Return on equity1.3%9.6%7.1%9.9%11.5%16.1%
Return on assets0.7%5.1%3.3%5.0%5.5%6.7%
Free cash flow yield5.4%6.6%6.0%4.3%4.3%6.8%
Revenue growth8.5%17.6%17.7%21.0%1.8%7.1%
Earnings growth-87.7%61.3%-8.7%-1.5%-17.4%-1.8%
Current ratio0.90x1.04x0.67x0.75x1.00x0.78x
Debt to equity0.30x0.41x0.60x0.34x0.46x0.71x
Equity ratio55.9%53.4%45.7%50.5%47.7%41.8%
Interest coverage9.68x4.54x3.66x8.31x8.91x9.89x
R&D as a share of sales11.5%13.6%12.6%12.5%12.8%10.4%
Buybacks as a share of market value-0.5%-1.2%-9.6%-5.2%-0.9%-0.2%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue14.5%13.1%24.2%
Operating income28.3%10.8%49.3%
Net income-43.4%-31.8%21.5%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin25.2%22.6%23.9%24.7%
Net margin8.0%9.9%12.2%14.0%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings242.728.438.024.419.614.413.120.625.133.9
Price to sales4.14.24.13.43.43.13.05.44.45.3

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.